KDx Diagnostics

KDx Diagnostics, Inc. is a company that develops novel diagnostic tests to enhance the early detection and management of cancer. KDx is the developer of the URO17 bladder cancer diagnostic test, one of the most sensitive and specific urine tests for bladder cancer. KDx is developing tests based on cell samples or cytology samples obtained from bodily fluids and washings, which can be acquired non-invasively to improve patient care. KDx will utilize new cutting-edge biomarkers to enhance the accuracy of cancer detection while leveraging existing testing platforms and infrastructure for the effective adoption of KDx tests in clinical settings.